Trial Profile
Phase 2 Study of AR201 Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2022
Price :
$35
*
At a glance
- Drugs AR-201 (Primary)
- Indications Food hypersensitivity
- Focus Therapeutic Use
- Sponsors Aimmune Therapeutics
- 03 Feb 2022 Status changed from completed to discontinued.
- 16 Jun 2021 Status changed from active, no longer recruiting to completed.
- 10 Apr 2020 Status changed from recruiting to active, no longer recruiting.